Together, this work elucidates the mechanism and demonstrates the clinical significance of ruxolitinib-mediated paradoxical hyperphosphorylation of JAK2-V617F and suggests that PIM kinase inhibitors are rational candidates for combination treatment with type I JAK inhibitors in MPN. This evidence concerns the gene JAK2 and myeloproliferative disorder.